General
AstraZeneca teams up with Russia’s Sputnik V vaccine for COVID-19 trials
AstraZeneca will start clinical trials to test a combination of its experimental COVID-19 vaccine with Russia’s Sputnik V shot, in a bid to boost the efficacy of the British drugmaker’s vaccine.
Key points:
- Moscow is likely to see the move as a vote of confidence in Sputnik V
- AstraZeneca, once seen as a frontrunner, has an average efficacy rate of 70.4 per cent
- Sanofi and GlaxoSmithKline vaccine trials show insufficient immune response in older people
Trials will start by the end of the year, according to Russia’s sovereign wealth fund, which has funded Sputnik V. The vaccine trial was named after the Soviet-era satellite that triggered the space race.
AstraZeneca said in a statement it was considering how it could assess combinations of…
-
Noosa News22 hours agoLaidley e-scooter death: Tragic new details after Summah Richards killed in freak accident
-
General23 hours agoMinjee Lee rallies after third-round meltdown to share fifth place at LA Championship
-
General17 hours agoUkraine says Russia has ramped up attacks despite ‘Easter truce’
-
General19 hours agoReason v magical climate thinking – voters have no choice